Immunome Inc. (IMNM): Total Liabilities
$48.84M
As of 2025-12-31
$40.30M
As of 2026-06-30
+87.6%
3-year compound annual growth
+72.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.84M | -17.3% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $59.08M | +106.1% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $28.66M | +287.6% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $7.39M | -24.1% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $9.74M | +206.3% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $3.18M | +77.1% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $1.80M | n/a | 2021-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Immunome Inc. (IMNM) | 2025-12-31 | $48.84M | -17.3% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $51.40M | +18.9% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $62.07M | -5.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
Compare IMNM, WHWK, OVID, XENE side by side · Screen every company in Pharmaceutical Preparations ↗